Please assess the completion status of the following clinical trial:

Trial Title: Vaccinating Children After Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Cases with ALL:~Inclusion Criteria:~* Diagnosed with standard, high-risk or very-high risk ALL~* Age at diagnosis: ≥1 year of age (age at enrollment: ≥3 years)~* Completed chemotherapy 3 to 12 months prior to enrollment~* No evidence of ALL relapse or secondary malignancy~* No known primary immunodeficiency~* No receipt of pneumococcal or tetanus-containing vaccines since completing chemotherapy~* No history of allergy to any component of PCV13~* Caregiver and/or participant is English or French-speaking and able to provide written informed consent~Exclusion Criteria:~* Infantile ALL~* Evidence of disease relapse or secondary malignancy~* History of underlying primary immunodeficiency~* Transplant recipient~* Received intravenous immunoglobulin (IVIG) within past 9 months or other blood products within the prior 3 months.Children who received PPV23 within 12 months of enrollment will not be eligible to receive PCV13 or PPV23. These children can still participate in the baseline evaluation, receive DTaP-Hib-IPV vaccine, and have tetanus and pertussis serology measured at 2 and 12-15 months post-immunization.~Controls:~Inclusion criteria~* Children 3-18 years of age, age-matched to cases~* Caregiver and/or participant is English or French-speaking and able to provide written informed consent~Exclusion criteria~* History of primary or secondary immunodeficiency including aplastic anemia, malignancy, nephrotic syndrome, malabsorption or severe malnutrition~* Immunosuppressive therapy within 3 months of enrollment (excluding inhaled corticosteroids)~* Received intravenous immunoglobulin (IVIG) within past 9 months or other blood products within the prior 3 months.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: ACTIVE_COMPARATOR): Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
- Healthy Control (Type: NO_INTERVENTION): Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).